Quick Answer
Beam Therapeutics Inc. reported Research And Development Expense of $409.62 million for the year ending 2025.
- Beam Therapeutics Inc. showed an increase of +11.4% in Research And Development Expense from 2024 to 2025.
- This data is from Beam Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $9.18 million | Q2 2019: $12.68 million | Q3 2019: $12.54 million | Q1 2020: $21.55 million | Q2 2020: $19.35 million | Q3 2020: $29.83 million | Q1 2021: $190.11 million | Q2 2021: $45.58 million | Q3 2021: $54.62 million | Q1 2022: $65.41 million | Q2 2022: $74.56 million | Q3 2022: $85.29 million | Q1 2023: $99.65 million | Q2 2023: $97.61 million | Q3 2023: $100.05 million | Q1 2024: $84.82 million | Q2 2024: $87.04 million | Q3 2024: $94.26 million | Q1 2025: $98.82 million | Q2 2025: $101.76 million | Q3 2025: $109.77 million.
- Over the full 7 years of available data (2019 to 2025), Beam Therapeutics Inc.'s Research And Development Expense has grown by 650.0%.
- Historical annual values: Fiscal year 2025: $409.62 million | Fiscal year 2024: $367.56 million | Fiscal year 2023: $437.38 million | Fiscal year 2022: $311.59 million | Fiscal year 2021: $387.09 million | Fiscal year 2020: $103.18 million | Fiscal year 2019: $54.62 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: